Galera Therapeutics, Inc. 8-K

What Happened
Galera Therapeutics (GRTX) and Obsidian Therapeutics announced on April 14, 2026 that they entered into a definitive Agreement and Plan of Merger under which both companies will be merged into subsidiaries of Gazelle Parent, Inc., with the combined company to be listed on Nasdaq. The transaction is structured so the mergers are intended to qualify as a tax‑free reorganization. Concurrently, Galera agreed to a $350.0 million PIPE (private investment in public equity) consisting of newly issued Series C convertible preferred stock that will convert into Parent common stock at closing. Galera and Obsidian also filed a press release and investor presentation under Regulation FD.

Key Details

• Transaction structure: Obsidian and Galera will each merge into Parent subsidiaries; Galera landholders receive Parent common stock per the exchange ratios in the Merger Agreement. Mergers intended to be tax‑free for U.S. federal income tax purposes.
• PIPE size and treatment: $350.0 million Concurrent PIPE via issuance of Series C non‑voting convertible preferred stock to institutional/accredited Investors; Series C converts to Galera common immediately then to Parent common at the Galera Effective Time.
• Pro forma ownership (assuming $350M PIPE and stated assumptions): Obsidian pre‑merger equityholders ~53.2% of combined company; PIPE Investors ~45.0%; Galera pre‑merger holders (excluding PIPE Investors) ~1.8% (fully diluted, treasury stock method).
• Valuations and assumptions used in allocation: Galera valued at $13.8M assuming Galera Net Cash of $1.8M at closing; Obsidian valued at $413.5M. Percentages are subject to adjustments (including final Galera net cash).
• Approvals & conditions: Closing requires Galera and Obsidian stockholder approvals (written consents), effectiveness of a Form S‑4 registering Parent shares, Nasdaq listing approval, receipt of PIPE proceeds, and customary closing conditions (no continuing material adverse effect).
• Protections and commitments: Support agreements signed by holders representing ~51.1% of Galera stock and ~62.8% of Obsidian stock; certain Obsidian insiders entered into 180‑day lock-up restrictions on shares received. Termination fees: $1.25M (payable by Obsidian in certain scenarios) and $0.75M (payable by Galera in certain scenarios).
• Contingent Value Right (CVR): Galera common stockholders of record immediately before the Galera Effective Time will receive one CVR per share that may pay if Parent or its affiliates receive proceeds from sale/license of Galera’s legacy small molecule tilarganine or specified supportive‑care products (avasopasem/ rucosopasem). CVRs are contractual, not equity, and may pay nothing.

Why It Matters
This 8‑K signals a transformational deal for Galera: the company will become part of a combined public company led by Gazelle Parent, with substantial new capital from a $350M PIPE. The financing and exchange ratios result in substantial dilution for existing Galera public holders — pro forma ownership by current Galera holders (excluding PIPE Investors) is projected to be very small (~1.8% under stated assumptions). The CVR provides a limited, contingent claim for potential future proceeds from legacy assets but does not guarantee payments. Closing remains subject to stockholder approvals, regulatory filings (Form S‑4), Nasdaq listing approval and receipt of PIPE funds, so investors should watch upcoming consent solicitations, the S‑4 filing/effectiveness, and PIPE closing updates.